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Abstract—Hypoglycemia or low blood glucose is unpleasant 
and can result in unconsciousness, seizures and even death.  It 
is a common and seruious side effect of insulin therapy in 
patients with diabetes. HypoMon is a non-invasive monitor that 
measures some physiological parameters continuously to 
provide detection of hypoglycemic episodes in Type 1 diabetes 
mellitus patients (T1DM). Based on heart rate and corrected 
QT interval of the ECG signal, we have continued to develop 
Bayesian neural network detection algorithms to recognize the 
presence of hypoglycemic episodes.  From a clinical study of 16 
children with T1DM, associated with nocturnal hypoglycemic 
episodes (natural occurrence), their heart rates increased 
(1.033±0.242 vs. 1.082±0.298, P<0.06) and their corrected QT 
intervals increased significantly (1.031±0.086 vs. 1.060±0.084, 
P<0.001). The overall data were organized into a training set (8 
patients) and a test set (another 8 patients) randomly selected. 
Using the optimal Bayesian neural network with 10 hidden 
nodes which was derived from the training set with the highest 
log evidence, the sensitivity (true positive) value for detection of 
hypoglycemia in the test set is 89.2%. 
I. INTRODUCTION 
ESULTS of the Diabetes Control and Complications Trial 
(DCCT) Research Group in 1993 [1] showed that 
intensive insulin therapy for a mean of six years 
(maintaining glycemic levels to a target HbA1c level of 7%) 
as opposed to conventional therapy (with resultant mean 
HbA1c level of 9%) significantly lowered the risk for 
retinopathy by 47%, nephropathy by 54% and for 
neuropathy by 60% [1-2].  
However, episodes of hypoglycemia, especially at night, 
were common among people treated for T1DM, largely 
because usual insulin preparations do not adequately mimic 
the normal patterns of endogenous insulin secretion [2]. In 
the DDCT, patients assigned to intensive therapy 
experienced a threefold increase incidence of severe 
hypoglycemic episodes over those receiving conventional 
therapy [1,3]. In that report, severe hypoglycemic episodes 
are defined as those in which the patient required assistance 
to treat the event and had documented blood glucose levels 
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less than 50 mg/dl (2.8 mmol/l). Thus hypoglycemia proved 
to be a limiting factor in achieving improved diabetes 
control. 
Symptoms of hypoglycemia arise from the activation of 
the autonomous central nervous systems (autonomic 
symptoms) and from reduced cerebral glucose consumption 
(neuroglycopenic symptoms), some of the latter being 
potentially life threatening. Autonomic symptoms (e.g., 
tachycardia, palpitations, shakiness, sweating) are activated 
before neuroglycopenic symptoms (e.g., reduced 
concentration, blurred vision, dizziness). Autonomic 
symptoms may provide the initial indication of the presence 
of hypoglycemia and allow the patient to recognise and 
correct the ensuing episode [6]. 
Nocturnal hypoglycemia is particularly dangerous 
because sleep reduces and may obscure autonomic counter-
regulatory responses, so that an initially mild episode may 
become severe. The risk of severe hypoglycemia is high at 
night, with at least 50% of all severe episodes occurring 
during that time [7]. Deficient glucose counter-regulation 
may also lead to severe hypoglycemia even with modest 
insulin elevations. 
Recently, we have developed an optimal Bayesian neural 
network algorithm for the detection of hypoglycaemic 
episodes in T1DM children using physiological parameters. 
Using the data from 25 children with T1DM volunteered for 
the 4-hour glucose clamp study to provide 28 sets of 
physiological responses, we have found that hypoglcyemic 
episodes in T1DM children can be detected non-invasively 
and continuously [8-9]. 
In this paper, we develop an optimal Bayesian neural 
network algorithm for the detection of natural occurrence of 
nocturnal hypoglycemic episodes in T1DM children using 
physiological parameters such as heart rate, corrected QT 
interval and skin impedance. Section II provides an 
overview of the method used for non-invasive and 
continuous detection of hypoglycemia. Section III presents 
the development and results of an optimal Bayesian neural 
network used for the identification of nocturnal 
hypoglycemic episodes in T1DM children. Section IV 
provides a conclusion for this study.  
II. METHODS 
A. Non-Invasive Hypoglycemia Monitor 
There is a limited number of non-invasive blood glucose 
monitoring systems currently available but each has specific 
drawbacks in terms of functioning, cost, reliability and 
obtrusiveness. Recently, GlucoWatch G2 Biographer from 
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Cygnus Inc was designed to measure glucose levels up to 3 
times per hour for 12 hours. The AutoSensor (the disposable 
component) which was attached to the back of the 
GlucoWatch monitor and adhered to the skin will provide 12 
hours of measurement. The product used reverse 
iontophoresis to extract and measure glucose levels non-
invasively using interstitial fluid. It had to be calibrated 
before each measurement period and required a two-hour 
warm-up period. It required costly disposable components, 
the gel pads must be replaced after each use, sweating might 
cause skipped readings, and the measurement had a time 
delay of about 10-15 minutes. As a result of these limitations 
this device is no longer available. 
Intensive research has been devoted to the development of 
hypoglycaemia alarms, exploiting principles that range from 
detecting changes in skin conductance (due to sweating) to 
measurements, by glucose sensors, of subcutaneous tissue 
glucose concentrations (Pickup, 2000; Rebrin; 1999). 
However, none of these have proved sufficiently reliable or 
unobtrusive.  
Although real-time continuous glucose monitoring systems 
(CGMS) are now available to give real-time estimations of 
glucose levels, these still lack the sensitivity to be used as 
alarms. For the MiniMed Medtronic (Northridge, CA) 
CGMS, the median error was reported as 10–15% at a 
plasma glucose of 4–10 mmol/l [10-12] and the low efficacy 
of CGMS (79.1% sensitivity) in detecting unrecognised 
hypoglycaemia has been confirmed [13]. For the Abbott 
Freestyle Navigator CGMS, the sensor accuracy was lowest 
during hypoglycaemia (3.9 mmol/l), with the median 
absolute relative difference (ARD) reported as 26.4% [14]. 
As these are median values, the errors may be significantly 
greater and, as a result, the manufacturers do not recommend 
their use as an alarm.  
We have developed a continuous non-invasive 
hypoglycemia monitor which uses physiological responses 
[8-9]. HypoMon® (Hypoglycemia Monitor) from AIMedics 
Pty Ltd (Fig. 1) is a non-invasive monitor that measures 
physiological parameters continuously to provide detection 
of hypoglycemic episodes in Type 1 diabetes mellitus 
patients (T1DM). The system consists of a battery-powered 
chest belt worn that houses a set of four skin-surface bio-
sensor electrodes for the measurement of physiological 
parameters and a hand-held receiver computer. 
The sensors are composed of a conductive polymer-based 
material such as polypyrrole which has low impedance and 
low noise characteristics. These characteristics enable the 
sensors to measure both skin impedance and quality ECG 
signals. The chest belt digitizes, encrypts and transmits the 
measured parameters to the receiver computer which 
analyzes and identifies hypoglycemic episodes. An alarm 























Fig. 1.  HypoMon  (AIMedics Pty Ltd) 
 
B. Bayesian Neural Network 
 Bayesian neural networks were firstly introduced by 
MacKay as a practical and powerful means to improve the 
generalisation of neural networks [16-19]. Bayesian learning 
of multi-layer perceptron neural networks is performed by 
considering Gaussian probability distributions of the weights 
which can give the best generalisation [16-17]. In particular, 
the weights w  in network X  are adjusted to their most 
probable values given the training data D . Specifically, the 
posterior distribution of the weights can be computed using 
Bayes’ rule as follows 
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where ( )XwDp ,|  is the likelihood function, which contains 
information about the weights from observations and the 
prior distribution ( )Xwp |  contains information about the 
weights from background knowledge. The 
denominator, ( )XDp | , is known as the evidence for 
network X . 
 Regularisation can be used to prevent any weights 
becoming excessively large, which can lead to poor 
generalisation. For a multi-layer perceptron neural network 
classifier with G  groups of weights and biases, a weight 
decay penalty term proportional to the sum of squares of the 
weights and biases is added to the data error function DE  to 
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where S  is called the cost function, gξ  is a non-negative 
scalar, sometimes knows as a hyperparameter, ensuring the 
distribution of weights and biases in group g  and gw  is the 




In network training, the hyperparameters are initialised to 
be arbitrary small values. The cost function is then 
minimised using an advanced optimisation technique. When 
the cost function has reached a local minimum, the 
hyperparameter gξ  ( Gg ,...,1= ) must be re-estimated. This 









ξ        (3) 
where H  is the Hessian matrix of DE  and gI  is the 
identity matrix, which selects weights in the g th group. The 
number of ‘well-determined’ weights gγ  in group g  is 
calculated based on the old value of gξ  as follows [15] 




γξ =   ),...,1( Gg =  (4) 
The hyperparameters need to be re-estimated several 
times until the cost function value ceases to change 
significantly between consecutive re-estimation periods. 
After the network training is completed, the values of 
parameters gγ  and gξ  are then used to compute the log 







































where gW  is the number of weights and biases in group g , 
and Ω  is set to be 310  [19]. However, Ω  is a minor factor 
because it is the same for all models and therefore does not 
effect to the relative comparison of log evidence of different 
network architectures. The above Equation is used to 
compare different networks having different numbers of 
hidden nodes. The best network will be selected with the 
highest log evidence. 
 
C. Study 
Sixteen children with T1DM volunteered for the 10-hour 
overnight hypoglycemia study at the Princess Margaret 
Hospital for Children in Perth, Australia. Each patient was 
monitored overnight for the natural occurrence of nocturnal 
hypoglycemia. Data were collected with approval from 
Women’s and Children’s Health Service, Department of 
Health, Government of Western Australia, and with 








Fig. 2.  Actual blood glucose level profiles in 16 T1DM children 
 
HypoMon was used to measure the required physiological 
parameters, while the actual blood glucose (BG) levels were 
collected as reference using Yellow Spring Instruments. The 
main parameters used for the detection of hypoglycemia are 
the heart rate, corrected QT interval and skin impedance. 
The actual blood glucose profiles for 16 T1DM children are 
shown in Fig. 2. 
III. RESULTS 
HypoMon was used to measure the relevant 
physiological responses. The four skin-surface bio-sensor 
electrodes are multiplexed and shared to measure both skin 
impedance and ECG signals. 
The responses from 16 T1DM children exhibit 
significant changes during the hypoglycemia phase against 
the non-hypoglycemia phase. Normalization was used to 
reduce patient-to-patient variability and to enable group 
comparison by dividing the patient’s heart rate, corrected 
QT interval and skin impedance by his/her corresponding 
values at time zero. The study shows that associated with 
hypoglycemic episodes in 16 T1DM children, using 
normalized values, their heart rates increase (1.082±0.298 
vs. 1.033±0.242, P<0.06) and their corrected QT intervals 
increase significantly (1.060±0.084 vs. 1.031±0.086, 
P<0.001). However, in this clinical study (natural 
occurrence), the reduction of skin impedances of the 
patients were not strong (1.111±1.460 vs. 1.108±1.277, 
P<0.984). It should noted that in our previous 4-hour 
glucose clamp study [8-9], skin impedances reduced 
significantly during hypoglycemic episodes.  
The detection of hypoglycemic episodes (BG<=60 
mg/dl) using these variables is based on an optimal 
Bayesian neural network algorithm developed from the 
obtained clinical data. This neural network has a multilayer 
feed-forward neural network structure with one hidden 
node layer and one output node layer. In effect, it estimates 




on the basis of the data at sampling period k and the 
previous data at sampling period k-1. In general, the 
sampling period is 5 minutes and approximately 30 data 
points are used for each patient. 
The overall data set consisted of a training set and a test 
set, each with 8 cases randomly selected. For these, the 
whole data set which included both hypoglycemia data part 
and non-hypoglycemia data part were used. For optimal 
robustness of the evaluation, we applied the evidence 
framework for Bayesian inference to the training set and 
found the feed forward neural network architecture with 10 
hidden nodes yielded the highest evidence as shown in Fig. 
3. The final feed-forward multi-layer neural network had 
heart rate, corrected QT interval and skin impedance as 
inputs, 10 hidden nodes and 1 output node (estimated blood 
glucose level). From the optimal neural network which was 
derived from the training set with the highest log evidence, 
the sensitivity (true positive) value for detection of 
hypoglycemia in the test set is 89.2%. 
IV. CONCLUSION 
The above result indicates that hypoglycemic episodes in 
T1DM children can be detected non-invasively and 
continuously effectively from the real-time physiological 
responses measured by HypoMon. It is noted that the 
relevant physiological parameters (QTc interval, heart rate 
and skin impedance) are less correlated to the actual blood 
glucose levels when the patients experienced hypoglycemic 
episodes through natural occurrence against the situation 
when clamp studies were performed. In this study, the 
sensitivity obtained by the hypoglycemia detection neural 
network is still low and its overall accuracy could be 
improved. A more advanced neural network algorithm will 
be developed to improve its overall accuracy further.  
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